ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSEAmerican:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the strengthening of its oncology leadership team with the formation of a Scientific Advisory Board (SAB) composed of key opinion leaders in oncolytic viruses and gene therapies. The SAB will work cohesively with the Synthetic Biologics’ leadership team to support the Company’s transformative clinical development strategy and extension into oncology.
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20badge%20holder-by%20hasrul_rais%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)